Abstract
Mass spectrometry biomarker discovery may assist patients diagnosis in time and realize the characteristics of new diseases. Our previous work built a preprocess method called HHTmass which is capable of removing noise, but HHTmass only a proof of principle to be peak detectable and did not tested for peak reappearance rate and used on medical data. We developed a modified version of biomarker discovery method called Enhance HHTMass (E-HHTMass) for MALDI-TOF and SELDI-TOF mass spectrometry data which improved old HHTMass method by removing the interpolation and the biomarker discovery process. E-HHTMass integrates the preprocessing and classification functions to identify significant peaks. The results show that most known biomarker can be found and high peak appearance rate achieved comparing to MSCAP and old HHTMass2. E-HHTMass is able to adapt to spectra with a small increasing interval. In addition, new peaks are detected which can be potential biomarker after further validation.
Keywords: Biomarker discovery, Hilbert-Huang transform, MALDI-TOF, Mass spectrometry, SELDI-TOF, HHTmass, MASCAP, Nephrological disease, Urinary hepcidin, Oral cancer:, SpecAlign, Denoising, WEKA, GUI
Protein & Peptide Letters
Title: Improved Candidate Biomarker Detection Based on Mass Spectrometry Data Using the Hilbert-Huang Transform
Volume: 19 Issue: 1
Author(s): Li-Ching Wu, Ping-Heng Hsieh, Jorng-Tzong Horng, Yu-Jen Jou, Chia-Der Lin, Kuang-Fu Cheng, Cheng-Wen Lin and Shih-Yin Chen
Affiliation:
Keywords: Biomarker discovery, Hilbert-Huang transform, MALDI-TOF, Mass spectrometry, SELDI-TOF, HHTmass, MASCAP, Nephrological disease, Urinary hepcidin, Oral cancer:, SpecAlign, Denoising, WEKA, GUI
Abstract: Mass spectrometry biomarker discovery may assist patients diagnosis in time and realize the characteristics of new diseases. Our previous work built a preprocess method called HHTmass which is capable of removing noise, but HHTmass only a proof of principle to be peak detectable and did not tested for peak reappearance rate and used on medical data. We developed a modified version of biomarker discovery method called Enhance HHTMass (E-HHTMass) for MALDI-TOF and SELDI-TOF mass spectrometry data which improved old HHTMass method by removing the interpolation and the biomarker discovery process. E-HHTMass integrates the preprocessing and classification functions to identify significant peaks. The results show that most known biomarker can be found and high peak appearance rate achieved comparing to MSCAP and old HHTMass2. E-HHTMass is able to adapt to spectra with a small increasing interval. In addition, new peaks are detected which can be potential biomarker after further validation.
Export Options
About this article
Cite this article as:
Wu Li-Ching, Hsieh Ping-Heng, Horng Jorng-Tzong, Jou Yu-Jen, Lin Chia-Der, Cheng Kuang-Fu, Lin Cheng-Wen and Chen Shih-Yin, Improved Candidate Biomarker Detection Based on Mass Spectrometry Data Using the Hilbert-Huang Transform, Protein & Peptide Letters 2012; 19 (1) . https://dx.doi.org/10.2174/092986612798472929
DOI https://dx.doi.org/10.2174/092986612798472929 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
MICA Gene and Relevance to Immune Responses in Organ Transplants and Inflammatory, Tumoral and Autoimmune Diseases
Current Immunology Reviews (Discontinued) Rho GTPase Effector Functions in Tumor Cell Invasion and Metastasis
Current Drug Targets Genetics and Genomics Interventions for Promoting Millets as Functional Foods
Current Genomics Angiotensin-(1-7): Blood, Heart, and Blood Vessels
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Familial Mutations and Post-translational Modifications of UCH-L1 in Parkinson's Disease and Neurodegenerative Disorders
Current Protein & Peptide Science Targeted Therapy for Advanced Renal Cell Cancer: Cytokines and Beyond
Current Pharmaceutical Design Turning Tumor-Promoting Copper into an Anti-Cancer Weapon via High-Throughput Chemistry
Current Medicinal Chemistry Recent Advances in Classical and Non-Classical Antifolates as Antitumor and Antiopportunistic Infection Agents: Part I
Anti-Cancer Agents in Medicinal Chemistry Ag+ Complexes as Potential Therapeutic Agents in Medicine and Pharmacy
Current Medicinal Chemistry Advancing Metabolomics Research and Biomarker Application with Nanotechnology
Current Metabolomics The Synergistic Effects of DNA-Targeted Chemotherapeutics and Histone Deacetylase Inhibitors As Therapeutic Strategies for Cancer Treatment
Current Medicinal Chemistry Novel Series of Coumarinyl Substituted-thiazolidin-2,4-dione Analogs as Anticancer Agents: Design, Synthesis, Spectral Studies and Cytotoxicity Evaluation
Anti-Cancer Agents in Medicinal Chemistry The Novel Functions of cGMP-Specific Phosphodiesterase 5 and its Inhibitors in Carcinoma Cells and Pulmonary/Cardiovascular Vessels
Current Topics in Medicinal Chemistry From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis
Current Neuropharmacology An Effective Approach of CT Lung Segmentation Using Possibilistic Fuzzy C-Means Algorithm and Classification of Lung Cancer Cells with the Aid of Soft Computing Techniques
Current Medical Imaging Stem Cell Therapy for Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Editorial (Thematic Issue : Frontier View on Drug Discoveries for Different Diseases - Part I )
Current Drug Metabolism Eriocalyxin B-Induced Apoptosis in Pancreatic Adenocarcinoma Cells Through Thiol-Containing Antioxidant Systems and Downstream Signalling Pathways
Current Molecular Medicine Somatostatin Receptor-Targeted Anti-Cancer Therapy
Current Drug Delivery Novel Systemic Drugs for Cutaneous T-Cell Lymphoma
Recent Patents on Anti-Cancer Drug Discovery